May 10, 2026 | Vyvgart Wins Broadest gMG Label; Merck Closes $6.7B Terns Deal

FDA approves Vyvgart for all adult gMG serotypes two daysbefore PDUFA — argenx locks in broadest MG label with no FcRn rival in seronegative disease. Plus Merck's $6.7B Terns completion, Avalo's Phase 2 HS win, and Gilead's billion-dollar PrEP forecast.www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Vyvgart,efgartigimod, argenx, myasthenia gravis, seronegative gMG, ADAPT SERON, Merck,Terns Pharmaceuticals, TERN-701, CML, chronic myeloid leukemia, Gilead,Yeztugo, PrEP, Biktarvy, Avalo Therapeutics, abdakibart, hidradenitissuppurativa, Viridian, elegrobart, thyroid eye disease, Celcuity, gedatolisib,breast cancer, Enhertu, Daiichi Sankyo, AstraZeneca, Odyssey Therapeutics, CellCentric,Bayer, Perfuse, Roche, PathAI, BioNTech, Leqembi, Entrada, FDA approval,M&A, IPO, J&Jpharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Vyvgart,efgartigimod, argenx, myasthenia gravis, seronegative gMG, ADAPT SERON, Merck,Terns Pharmaceuticals, TERN-701, CML, chronic myeloid leukemia, Gilead,Yeztugo, PrEP, Biktarvy, Avalo Therapeutics, abdakibart, hidradenitissuppurativa, Viridian, elegrobart, thyroid eye disease, Celcuity, gedatolisib,breast cancer, Enhertu, Daiichi Sankyo, AstraZeneca, Odyssey Therapeutics, CellCentric,Bayer, Perfuse, Roche, PathAI, BioNTech, Leqembi, Entrada, FDA approval,M&A, IPO, J&Jpharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Vyvgart,efgartigimod, argenx, myasthenia gravis, seronegative gMG, ADAPT SERON, Merck,Terns Pharmaceuticals, TERN-701, CML, chronic myeloid leukemia, Gilead,Yeztugo, PrEP, Biktarvy, Avalo Therapeutics, abdakibart, hidradenitissuppurativa, Viridian, elegrobart, thyroid eye disease, Celcuity, gedatolisib,breast cancer, Enhertu, Daiichi Sankyo, AstraZeneca, Odyssey Therapeutics, CellCentric,Bayer, Perfuse, Roche, PathAI, BioNTech, Leqembi, Entrada, FDA approval,M&A, IPO, J&J